CA2654041A1 - Stable aerosol pharmaceutical formulations - Google Patents
Stable aerosol pharmaceutical formulations Download PDFInfo
- Publication number
- CA2654041A1 CA2654041A1 CA002654041A CA2654041A CA2654041A1 CA 2654041 A1 CA2654041 A1 CA 2654041A1 CA 002654041 A CA002654041 A CA 002654041A CA 2654041 A CA2654041 A CA 2654041A CA 2654041 A1 CA2654041 A1 CA 2654041A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- formulation
- polyoxyethylene
- formulation according
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 239000000443 aerosol Substances 0.000 title abstract description 14
- 229940125388 beta agonist Drugs 0.000 claims abstract description 46
- 239000006184 cosolvent Substances 0.000 claims abstract description 36
- 239000004094 surface-active agent Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 17
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 14
- 208000006673 asthma Diseases 0.000 claims abstract description 12
- 230000007885 bronchoconstriction Effects 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 106
- 238000009472 formulation Methods 0.000 claims description 104
- 239000003380 propellant Substances 0.000 claims description 58
- 239000000812 cholinergic antagonist Substances 0.000 claims description 41
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 39
- 239000000725 suspension Substances 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 31
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 29
- 239000012453 solvate Substances 0.000 claims description 29
- 229940057282 albuterol sulfate Drugs 0.000 claims description 27
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 27
- 239000000651 prodrug Substances 0.000 claims description 27
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 26
- 229960002052 salbutamol Drugs 0.000 claims description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 229960001888 ipratropium Drugs 0.000 claims description 24
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 19
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims description 16
- 229920000136 polysorbate Polymers 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229950008882 polysorbate Drugs 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 229940071648 metered dose inhaler Drugs 0.000 claims description 12
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 11
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 11
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 11
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000005642 Oleic acid Substances 0.000 claims description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 7
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 7
- 229940110309 tiotropium Drugs 0.000 claims description 7
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 6
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 6
- 208000014181 Bronchial disease Diseases 0.000 claims description 6
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 6
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 6
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 6
- 229960002848 formoterol Drugs 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 229950008204 levosalbutamol Drugs 0.000 claims description 6
- 229960005414 pirbuterol Drugs 0.000 claims description 6
- 229960004017 salmeterol Drugs 0.000 claims description 6
- 229960001361 ipratropium bromide Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 235000021313 oleic acid Nutrition 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 3
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 3
- 229920005549 butyl rubber Polymers 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920001038 ethylene copolymer Polymers 0.000 claims description 2
- 229920002313 fluoropolymer Polymers 0.000 claims description 2
- 150000004682 monohydrates Chemical class 0.000 claims description 2
- 230000001078 anti-cholinergic effect Effects 0.000 abstract description 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 26
- 229960002630 ipratropium bromide monohydrate Drugs 0.000 description 21
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 20
- 239000002245 particle Substances 0.000 description 18
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 13
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 13
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 229920003080 Povidone K 25 Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- IIQAZFRPESFLAT-UHFFFAOYSA-N C(CCCCCCCC=C/CCCCCCCC)(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)O.S(=O)(=O)(O)O Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)O.C(CCCCCCCC=C/CCCCCCCC)(=O)O.S(=O)(=O)(O)O IIQAZFRPESFLAT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004813 Perfluoroalkoxy alkane Substances 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229920011301 perfluoro alkoxyl alkane Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN918MU2006 | 2006-06-12 | ||
| IN918/MUM/2006 | 2006-06-12 | ||
| PCT/GB2007/002183 WO2007144604A1 (en) | 2006-06-12 | 2007-06-12 | Stable aerosol pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2654041A1 true CA2654041A1 (en) | 2007-12-21 |
Family
ID=38510317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002654041A Abandoned CA2654041A1 (en) | 2006-06-12 | 2007-06-12 | Stable aerosol pharmaceutical formulations |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070286814A1 (enExample) |
| EP (1) | EP2040670A1 (enExample) |
| JP (1) | JP2009539958A (enExample) |
| KR (1) | KR20090033355A (enExample) |
| AU (1) | AU2007259064A1 (enExample) |
| BR (1) | BRPI0711688A2 (enExample) |
| CA (1) | CA2654041A1 (enExample) |
| CL (1) | CL2007001686A1 (enExample) |
| MX (1) | MX2008015589A (enExample) |
| PE (1) | PE20080204A1 (enExample) |
| RU (1) | RU2009100156A (enExample) |
| WO (1) | WO2007144604A1 (enExample) |
| ZA (1) | ZA200810142B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8425459B2 (en) * | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US20130160761A1 (en) * | 2008-11-04 | 2013-06-27 | Cipla Limited | Pharmaceutical Aerosol Composition |
| EP3143987A1 (en) * | 2010-08-03 | 2017-03-22 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| TWI399202B (zh) * | 2011-03-17 | 2013-06-21 | Intech Biopharm Ltd | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
| EP3174522A1 (en) * | 2014-07-29 | 2017-06-07 | 3M Innovative Properties Company | Method of preparing a pharmaceutical composition |
| US20180071231A1 (en) * | 2015-04-10 | 2018-03-15 | 3M Innovative Properties Company | Formulation and aerosol canisters, inhalers, and the like containing the formulation |
| US20160310410A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| US10231948B2 (en) | 2017-02-27 | 2019-03-19 | Jason Ty Nguyen | Metered dose inhaler compositions, systems, and methods |
| TWM605214U (zh) * | 2018-06-29 | 2020-12-11 | 美商Ｃｓｐ技術股份有限公司 | 低氣味或無氣味吸入器 |
| NL2036216B1 (en) * | 2023-11-08 | 2025-05-19 | Jove Beheer B V | Water drainage system for draining water into an aquifer |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555319A (enExample) * | 1956-03-21 | 1900-01-01 | ||
| US2885427A (en) * | 1956-11-15 | 1959-05-05 | Dow Chemical Co | Fluorination of trichloroethylene |
| BE556587A (enExample) * | 1957-01-31 | 1957-04-11 | ||
| US3095355A (en) * | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
| NL289785A (enExample) * | 1962-11-29 | |||
| US3250808A (en) * | 1963-10-31 | 1966-05-10 | Du Pont | Fluorocarbon ethers derived from hexafluoropropylene epoxide |
| US3261748A (en) * | 1964-07-17 | 1966-07-19 | Dow Chemical Co | 1,1,1,2-tetrafluoroethane anesthetic |
| GB1114313A (en) * | 1964-11-19 | 1968-05-22 | Wyeth John & Brother Ltd | Pharmaceutical compositions |
| GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| US3551558A (en) * | 1967-08-18 | 1970-12-29 | Eisai Co Ltd | Therapeutical aerosol composition and preparation thereof |
| US3505337A (en) * | 1967-12-22 | 1970-04-07 | Boehringer Sohn Ingelheim | N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof |
| US4143204A (en) * | 1971-12-27 | 1979-03-06 | E. I. Du Pont De Nemours And Company | Articles coated with fluorocarbon resins |
| US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) * | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| US4025635A (en) * | 1972-09-06 | 1977-05-24 | Burroughs Wellcome Co. | Cyclic sulphur compounds |
| US4011661A (en) * | 1973-10-30 | 1977-03-15 | Kyowa Hakko Kogyo Co., Ltd. | Powdered emulsion product and method of production |
| US3987192A (en) * | 1974-01-07 | 1976-10-19 | The Upjohn Company | Compositions and process of treatment |
| US4405598A (en) * | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
| NL7708731A (nl) * | 1976-08-13 | 1978-02-15 | Montedison Spa | Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen. |
| US4129603A (en) * | 1978-02-07 | 1978-12-12 | Imperial Chemical Industries Limited | Manufacture of halogenated compounds |
| DE2903957A1 (de) * | 1979-02-02 | 1980-08-07 | Boehringer Sohn Ingelheim | Mittel zur behandlung der nasalen hypersekretion |
| DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| US4352789A (en) * | 1980-03-17 | 1982-10-05 | Minnesota Mining And Manufacturing Company | Aerosol compositions containing finely divided solid materials |
| EP0072046B1 (en) * | 1981-07-24 | 1986-01-15 | FISONS plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
| US4476130A (en) * | 1982-09-09 | 1984-10-09 | Riker Laboratories, Inc. | 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US4671270A (en) * | 1984-07-06 | 1987-06-09 | Midori Anzen Industry Co., Ltd. | Portable oxygen inhaler |
| US4621116A (en) * | 1984-12-07 | 1986-11-04 | E. I. Du Pont De Nemours And Company | Process for copolymerization of tetrafluoroethylene in the presence of a dispersing agent comprising a perfluoroalkoxybenzene sulfonic acid or salt |
| GB8432063D0 (en) * | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
| GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| EP0223831B1 (en) * | 1985-05-22 | 1992-07-15 | Liposome Technology, Inc. | Liposome inhalation method and system |
| AU597049B2 (en) * | 1986-03-10 | 1990-05-24 | Kurt Burghart | Pharmaceutical preparation containing nifedipine |
| WO1987005210A1 (fr) * | 1986-03-10 | 1987-09-11 | Kurt Burghart | Produit pharmaceutique et son procede de preparation |
| US5093403A (en) * | 1986-07-01 | 1992-03-03 | Edlon Products, Inc. | Polymer-metal bonded composite and method of producing same |
| US5536583A (en) * | 1986-07-01 | 1996-07-16 | Edlon Products, Inc. | Polymer metal bonded composite and method of producing same |
| US4819834A (en) * | 1986-09-09 | 1989-04-11 | Minnesota Mining And Manufacturing Company | Apparatus and methods for delivering a predetermined amount of a pressurized fluid |
| US4929317A (en) * | 1986-12-01 | 1990-05-29 | Tokuyama Soda Kabushiki Kaisha | Process for preparation of perfluoro organic compounds |
| US4752466A (en) * | 1987-08-31 | 1988-06-21 | Johnson & Johnson Products, Inc. | Thrombin aerosol |
| US4889656A (en) * | 1987-10-30 | 1989-12-26 | Minnesota Mining And Manufacturing Company | Perfluoro(cycloaliphatic methyleneoxyalkylene) carbonyl fluorides and derivatives thereof |
| US4834083A (en) * | 1988-05-12 | 1989-05-30 | Minnesota Mining And Manufacturing Company | Aerosol device |
| ATE107854T1 (de) * | 1988-09-30 | 1994-07-15 | Rhone Poulenc Rorer Ltd | Pharmazeutisches granulat. |
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| GB8909891D0 (en) * | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
| FR2649359B1 (fr) * | 1989-07-06 | 1993-02-12 | Cebal | Bande ou portion de bande pour emboutissage ou emboutissage-etirage, et son utilisation |
| GB8917285D0 (en) * | 1989-07-28 | 1989-09-13 | Harris Pharma Ltd | A valve for an aerosol dispenser |
| US5208226A (en) * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
| US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
| GB9001635D0 (en) * | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
| US5062423A (en) * | 1990-02-27 | 1991-11-05 | Minnesota Mining And Manufacturing Company | Equine aerosol drug delivery method and apparatus |
| US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| US5126123A (en) * | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
| US5223343A (en) * | 1990-12-12 | 1993-06-29 | E. I. Du Pont De Nemours And Company | Non-stick coating system with high and low melt viscosity PTFE for concentration gradient |
| US5190029A (en) * | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
| US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
| SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| ES2200771T3 (es) * | 1991-06-10 | 2004-03-16 | Schering Corporation | Formulaciones en aerosol no clorofluorocarbonadas. |
| US6123924A (en) * | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
| US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
| US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| GB9200148D0 (en) * | 1992-01-06 | 1992-02-26 | Minnesota Mining & Mfg | Aerosol valves |
| GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| DE69306379T2 (de) * | 1992-03-10 | 1997-06-12 | Fisons Plc | Inhalierbare arzneimittel |
| DE4230876A1 (de) * | 1992-03-17 | 1993-09-23 | Asta Medica Ag | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten |
| KR100225983B1 (ko) * | 1992-10-26 | 1999-10-15 | 클라우스-디터 홈메리히, 디트리히 빌헬름 샤흐트 | 마이크로캡슐의 제조 방법 |
| US5569450A (en) * | 1993-03-17 | 1996-10-29 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
| US5492688A (en) * | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
| US5348731A (en) * | 1993-05-19 | 1994-09-20 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Aerosol spray steel can dispensers with corrosion inhibitors |
| DE4329446A1 (de) * | 1993-09-01 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen |
| PT731688E (pt) * | 1993-12-02 | 2003-07-31 | Abbott Lab | Formulacoes de farmacos em aerossol para utilizacao com propulsores sem cfc |
| US5467900A (en) * | 1994-03-16 | 1995-11-21 | Afa Products, Inc. | Precompression valve for trigger sprayer |
| US5508023A (en) * | 1994-04-11 | 1996-04-16 | The Center For Innovative Technology | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant |
| GB9420971D0 (en) * | 1994-05-06 | 1994-12-07 | Minnesota Mining & Mfg | Aerosol valves |
| DE4427175A1 (de) * | 1994-08-01 | 1996-02-08 | Coster Tecnologie Speciali Spa | Baueinheit |
| US5647347A (en) * | 1994-10-21 | 1997-07-15 | Glaxo Wellcome Inc. | Medicament carrier for dry powder inhalator |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5653961A (en) * | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| SI0820279T1 (en) * | 1995-04-14 | 2002-12-31 | Smithkline Beecham Corporation | Metered dose inhaler for albuterol |
| US5667806A (en) * | 1995-06-07 | 1997-09-16 | Emisphere Technologies, Inc. | Spray drying method and apparatus |
| US5603918A (en) * | 1995-06-09 | 1997-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aerosol composition of a salt of ipratropium and a salt of albuterol |
| KR100600423B1 (ko) * | 1998-06-18 | 2006-07-13 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 2개 이상의 활성 물질을 포함하는 연무질 약제학적 제형 |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| GB0008485D0 (en) * | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| JP5392880B2 (ja) * | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| GB0106046D0 (en) * | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Canister |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| RU2327450C2 (ru) * | 2002-08-29 | 2008-06-27 | Сипла Лимитед | Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды |
| BRPI0512878A (pt) * | 2004-07-02 | 2008-04-15 | Boehringer Ingelheim Int | formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| US20070264202A1 (en) * | 2004-09-09 | 2007-11-15 | Cipla Limited | Pharmaceutical Composition Comprising an Isomer of Betamimetic Agent and an Anti-Cholinergic Agent |
-
2006
- 2006-09-21 US US11/533,857 patent/US20070286814A1/en not_active Abandoned
-
2007
- 2007-06-11 PE PE2007000733A patent/PE20080204A1/es not_active Application Discontinuation
- 2007-06-11 CL CL200701686A patent/CL2007001686A1/es unknown
- 2007-06-12 KR KR1020097000418A patent/KR20090033355A/ko not_active Withdrawn
- 2007-06-12 EP EP07733191A patent/EP2040670A1/en not_active Withdrawn
- 2007-06-12 JP JP2009514892A patent/JP2009539958A/ja active Pending
- 2007-06-12 WO PCT/GB2007/002183 patent/WO2007144604A1/en not_active Ceased
- 2007-06-12 ZA ZA200810142A patent/ZA200810142B/en unknown
- 2007-06-12 RU RU2009100156/15A patent/RU2009100156A/ru not_active Application Discontinuation
- 2007-06-12 US US12/304,363 patent/US20090191134A1/en not_active Abandoned
- 2007-06-12 MX MX2008015589A patent/MX2008015589A/es not_active Application Discontinuation
- 2007-06-12 CA CA002654041A patent/CA2654041A1/en not_active Abandoned
- 2007-06-12 AU AU2007259064A patent/AU2007259064A1/en not_active Abandoned
- 2007-06-12 BR BRPI0711688-8A patent/BRPI0711688A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070286814A1 (en) | 2007-12-13 |
| JP2009539958A (ja) | 2009-11-19 |
| EP2040670A1 (en) | 2009-04-01 |
| CL2007001686A1 (es) | 2008-03-14 |
| KR20090033355A (ko) | 2009-04-02 |
| MX2008015589A (es) | 2009-03-20 |
| US20090191134A1 (en) | 2009-07-30 |
| AU2007259064A1 (en) | 2007-12-21 |
| RU2009100156A (ru) | 2010-07-20 |
| PE20080204A1 (es) | 2008-04-11 |
| ZA200810142B (en) | 2009-11-25 |
| BRPI0711688A2 (pt) | 2012-01-17 |
| WO2007144604A1 (en) | 2007-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090191134A1 (en) | Stable aerosol pharmaceutical formulations | |
| CA2477881C (en) | Formoterol superfine formulation | |
| KR101757951B1 (ko) | Ｃｏｐｄ용 조합요법 | |
| SK13342003A3 (sk) | Lekárske aerosólové prípravky | |
| EP2124915A2 (en) | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid | |
| SK92494A3 (en) | Pharmaceutical agent | |
| ZA200406919B (en) | Formoterol superfine formulation | |
| EP4585215A1 (en) | Pharmaceutical composition for inhalation for preventing or treating respiratory disease | |
| EP1553922B1 (en) | Salmeterol superfine formulation | |
| EP2482799B1 (en) | Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate | |
| AU2021356146A1 (en) | A pharmaceutical formulation for pressurised metered dose inhaler | |
| EP1811981B1 (en) | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister | |
| US20090180969A1 (en) | Pharmaceutical formulation comprising an anticholinergic drug | |
| WO2008047239A2 (en) | Stable aerosol pharmaceutical formulations | |
| EA048425B1 (ru) | Фармацевтический состав для дозирующего аэрозольного ингалятора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130612 |